Sticking close to innovation roots, Arch Venture Partners raises oversubscribed $400M fund Arch Venture Partners has operated longer than most venture capital firms by sticking close to its knitting. And now the… Read More
Stem cell biology company Fate Therapeutics files for $69 million IPO Could this be another example of a startup that got away? Fate Therapeutics, which started in Seattle six years ago… Read More
MicroRNA startup Groove Biopharma scores $6 million It’s been a bit slow in Seattle venture capital circles in the past few months. But some of the region’s… Read More
Theraclone Sciences raises $10M Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors… Read More
Impinj files for $100 million IPO For the second time this week, a Seattle technology company has filed to go public. This time it is Impinj,… Read More
